Neopharma Technologies and Impairment Science Strengthen Partnership to Revolutionize Drug and Impairment Testing
contract
February 04, 2025
PERTH, Australia, Feb. 4, 2025 /PRNewswire/ -- This partnership enables Neopharma to introduce a groundbreaking solution that combines drug testing with impairment testing to fill a crucial gap in the market. With the continued expansion of marijuana legalization across the U.S. and worldwide, the need for accurate and reliable impairment assessment tools has never been greater. Directly addressing the growing challenges faced by employers and safety-sensitive industries, this integrated solution allows organizations to conduct, interpret, and report thousands of drug test results alongside cognitive impairment assessments.
The combined data, accessible through Neopharma's NEOVAULT® app, is now available on Apple's App Store and Google Play. It empowers employers with real-time insights, significantly improving decision-making in the increasingly complex legal cannabis landscape.
Impairment Science CEO Rob Schiller, expressing his enthusiasm about the partnership, stated, "We are absolutely thrilled to be working more closely with Neopharma Technologies. Indeed, we hope to deepen the relationship with greater collaboration and integration over time. The combination of our two innovative technologies and products—drug testing and impairment testing—launches a long-awaited new era in on-the-job safety and productivity."
Nina M. French, CEO of Neopharma Technologies, underscoring the importance of this innovation, stated, "This marks a significant advancement for employers in the U.S. and ultimately worldwide as we leverage advanced technologies to meaningfully measure and address drug impairment. Partnering with Impairment Science enables us to deliver a groundbreaking solution in 2025 to workplaces. Follow-on applications will extend to roadside testing, student testing, and research. By combining data with expertise, we are defining drug impairment with much greater clarity.
This combination addresses a longstanding issue that has only grown more complex since the medical legalization of cannabis in 1996 and ongoing recreational legalization since 2012. This strategic alliance underscores both Neopharma Technologies and Impairment Science's commitment to innovation, safety, and providing actionable insights to our partners, driving value and leadership in a critical market."
About Neopharma Technologies
Neopharma Technologies Ltd., dedicated to developing cutting-edge solutions that address pressing industry needs, has created the next generation of drug testing. Our commitment to advancing technology and improving efficiency drives our mission to deliver exceptional products and services.
About Impairment Science
Impairment Science specializes in cognitive impairment technologies, providing solutions, including DRUID, its fit-for-duty app, that enhance workplace safety and productivity. Our innovative approach, using neuroscience, ensures rapid, accurate, and objective assessments of cognitive function, supporting a safer, less costly work environment.
Contact: Shaun Melville, shaun@neopharmatechnologies.com
View original content:https://www.prnewswire.com/apac/news-releases/neopharma-technologies-and-impairment-science-strengthen-partnership-to-revolutionize-drug-and-impairment-testing-302367247.html
SOURCE Neopharma Technologies
AAPR aggregates press releases and media statements from around the world to assist our news partners with identifying and creating timely and relevant news. All of the press releases published on this website are third-party content and AAP was not involved in the creation of it. Read the full terms.
